Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 25695682 | HLA-DQB1*02 | rosacea | NA | NA | rs763035 | positive | |
| in addition, three hla alleles, all mhc class ii proteins, were significantly associated with rosacea in the discovery group and confirmed in the replication group: hla-drb1*03:01 (p=1.0 x 10(-8) discovery group; p=4.4 x 10(-6) replication group), hla-dqb1*02:01 (p=1.3 x 10(-8) discovery group; p=7.2 x 10(-6) replication group), and hla-dqa1*05:01 (p=1.4 x 10(-8) discovery group; p=7.6 x 10(-6) replication group). | |||||||
| 25695682 | HLA (HLA) | papulopustular rosacea | NA | NA | rs763035 | unclassified | |
| exploratory immunohistochemical analysis of hla-dra and btnl2 expression in papulopustular rosacea lesions from six individuals, including one with the rs763035 variant, revealed staining in the perifollicular inflammatory infiltrate of rosacea for both proteins. | |||||||
| 29499803 | HLA (HLA) | rosacea | European | NA | NA | only_studied | |
| currently, one single-nucleotide polymorphism has been identified in association with rosacea and is intergenic between hla-dra and btnl2. | |||||||
| 29499803 | HLA (HLA) | rosacea | European | NA | NA | unclassified | |
| additional associations with hla alleles and immune-mediated disorders support the role of immune-regulating genes and innate and adaptive immunity in rosacea. | |||||||
| 29771307 | HLA (HLA) | rosacea | European | NA | rs1805007 | unclassified | |
| all associations with rosacea were novel except for the hla locus. | |||||||
| 29771307 | HLA (HLA) | rosacea | European | NA | rs1805007 | unclassified | |
| genes within three loci (psmb9-hla-dma, herc-oca2 and nrx3-dio2) were differentially expressed in a previously published clinical rosacea transcriptomics study that compared lesional to non-lesional samples. | |||||||
| 11055515 | HLA (HLA) | pulmonary injury | NA | NA | NA | unclassified | |
| although there are two purported mechanisms of injury, the preponderance of evidence suggests that passively transfused complement-activating antibodies (either granulocyte or hla-specific) act as mediators, which result in granulocyte aggregation, activation, and microvascular pulmonary injury. | |||||||
| 24188917 | HLA MATCHED (HLA-MATCHED) | pulmonary injury | NA | NA | NA | unclassified | |
| to characterize the kinetics of recovery from pulmonary injury in long-term survivors, we collected data on 138 subjects who survived > 3 years (median survival, 10.2 years) after predominantly tbi-based allo-sct from their hla-matched siblings. | |||||||
| 11057507 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | listeriosis | NA | NA | NA | unclassified | |
| listeriosis is a rare complication in allogeneic bone marrow transplant recipients; however, the widespread practice of performing transplants from a donor-alternative to a human leukocyte antigen-compatible sibling and, in this setting, the need for intensified immunosuppression may predict an increasing and earlier occurrence of listeriosis. | |||||||
| 12507821 | HLA-DRB1 (HLA-DRB1) | insulin | Mexican | glucose | NA | unclassified | |
| NA | |||||||
Copyright 2024